Aileron Therapeutics (ALRN) Receives a Rating Update from a Top Analyst

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aileron Therapeutics (ALRNResearch Report), with a price target of $3.00. The company’s shares closed last Monday at $1.47.

According to, White is a top 100 analyst with an average return of 31.8% and a 54.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Currently, the analyst consensus on Aileron Therapeutics is a Strong Buy with an average price target of $4.33, representing a 151.7% upside. In a report issued on May 27, JonesTrading also reiterated a Buy rating on the stock with a $5.00 price target.

See today’s analyst top recommended stocks >>

Based on Aileron Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.75 million. In comparison, last year the company had a GAAP net loss of $7.21 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.